Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AIMMUNE THERAPEUTICS, INC.

(AIMT)
 SummaryChartsNewsRatingsCompany 
Quotes 5-day view   End-of-day quote. End-of-day quote Nasdaq
03/25/2020 03/26/2020 03/27/2020 03/30/2020 03/31/2020 Date
13.85 14.44 13.98 14.55 14.42 Last
1849173 1510712 1006961 1471412 1413928 Volume
+0.14% +4.26% -3.19% +4.08% -0.89% Change
Company
Aimmune Therapeutics, Inc. is a biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens. PALFORZIA is its internally developed product utilizing CODIT.... 
More about the company
Ratings of Aimmune Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about AIMMUNE THERAPEUTICS, INC.
02/18PRESS RELEASE : Nestle: Nestlé reports full-year -2-
DJ
01/22AIMMUNE THERAPEUTICS  : European Commission approves Aimmune's PALFORZIA as firs..
AQ
01/05AIMMUNE THERAPEUTICS  : European Commission approves first treatment for peanut ..
AQ
2020AIMMUNE THERAPEUTICS  : European Commission approves Aimmune's PALFORZIA as firs..
AQ
2020AIMMUNE THERAPEUTICS  : European Commission Approves Aimmune's PALFORZIA® as Fir..
BU
2020Nestle shrugs off COVID-19 impact thanks to pet food and health nutrition
RE
2020AIMMUNE THERAPEUTICS, INC.  : Termination of a Material Definitive Agreement, Co..
AQ
2020AIMMUNE THERAPEUTICS  : Receives Positive CHMP Opinion on PALFORZIA for the Trea..
AQ
2020MONTEVERDE & ASSOCIATES PC  : Files Class Action Lawsuit On Behalf Of Shareholde..
PR
2020AIMMUNE THERAPEUTICS  : Nestle Completes Acquisition of Aimmune Therapeutics
AQ
2020AIMMUNE THERAPEUTICS  : Nestle announces results of tender offer for Aimmune The..
AQ
2020GLOBAL MARKETS LIVE: U.S. banks beat expectations
2020Nestle Completes Purchase of Aimmune Therapeutics Shares; Plans Merger With S..
DJ
2020AIMMUNE THERAPEUTICS  : shareholders accept $2 billion Nestle tender offer
RE
2020Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics..
PR
More news
News in other languages on AIMMUNE THERAPEUTICS, INC.
2020Bourse Zurich: la nouvelle variante du coronavirus effraie le marché
2020Bourse Zurich: toujours plombée par les craintes sur la nouvelle souche de vi..
2020Bourse Zurich: les craintes sur la nouvelle souche de virus l'emportent
2020Nestlé fait une percée pour traiter l'allergie aux arachides
2020Bourse Zurich: la mutation du coronavirus effraie les investisseurs
More news
Chart AIMMUNE THERAPEUTICS, INC.
Duration : Period :
Aimmune Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
NameTitle
Mark D. McDade Chairman
Daniel C. Adelman Chief Medical Officer
Narinder Singh Executive Vice President-Technical Operations
Patrick G. Enright Independent Non-Employee Director
Stacey Denenberg Seltzer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AIMMUNE THERAPEUTICS, INC.0.00%2 268
GILEAD SCIENCES, INC.16.98%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE170.58%57 615
REGENERON PHARMACEUTICALS9.45%54 424
VERTEX PHARMACEUTICALS-17.58%49 966